Clare L. Scott

38.7k total citations · 8 hit papers
177 papers, 13.3k citations indexed

About

Clare L. Scott is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Clare L. Scott has authored 177 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 58 papers in Molecular Biology and 48 papers in Reproductive Medicine. Recurrent topics in Clare L. Scott's work include PARP inhibition in cancer therapy (49 papers), Ovarian cancer diagnosis and treatment (44 papers) and BRCA gene mutations in cancer (30 papers). Clare L. Scott is often cited by papers focused on PARP inhibition in cancer therapy (49 papers), Ovarian cancer diagnosis and treatment (44 papers) and BRCA gene mutations in cancer (30 papers). Clare L. Scott collaborates with scholars based in Australia, United Kingdom and United States. Clare L. Scott's co-authors include Michael Friedländer, Ursula A. Matulonis, Andreas Strasser, James Carmichael, Jonathan A. Ledermann, Charlie Gourley, Tamar Safra, Philipp Harter, Werner Meier and Ronnie Shapira‐Frommer and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Clare L. Scott

171 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

2010 1.7k citations Michael Friedländer, Clare L. Scott et al. profile →
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

2006 1.0k citations Cassandra J. Vandenberg, Clare L. Scott et al. profile →
Target-enrichment strategies for next-generation sequencing

2010 841 citations Clare L. Scott et al. profile →
SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine

1999 635 citations Clare L. Scott et al. profile →
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

2020 261 citations Alexandra Léary, Clare L. Scott et al. Annals of Oncology profile →

Peers

Clare L. Scott

ONCOL

GENET

IMMUN

Cynthia C. Morton United States

Alan Ashworth United Kingdom

Bruce A.J. Ponder United Kingdom

David Robertson Australia

Luigi Frati Italy

Fumihiko Matsuda Japan

Gerald R. Cunha United States

Edwin Cuppen Netherlands

Robert B. Jaffe United States

Ninette Amariglio Israel

Cynthia C. Morton United States

Clare L. Scott

2.2k ×0.3

ONCOL

8.7k ×1.3

1.3k ×0.5

2.9k ×1.1

GENET

2.3k ×1.2

IMMUN

Citations per year, relative to Clare L. Scott Clare L. Scott (= 1×) peers Cynthia C. Morton

Countries citing papers authored by Clare L. Scott

Since Specialization

Citations

This map shows the geographic impact of Clare L. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clare L. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clare L. Scott more than expected).

Fields of papers citing papers by Clare L. Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clare L. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clare L. Scott. The network helps show where Clare L. Scott may publish in the future.

Co-authorship network of co-authors of Clare L. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Clare L. Scott. A scholar is included among the top collaborators of Clare L. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clare L. Scott. Clare L. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nesic, Ksenija, Katherine A. Rybinski, Gwo‐Yaw Ho, et al.. (2025). Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models. Clinical and Translational Medicine. 15(3). e70274–e70274. 1 indexed citations

Tan, David S.P., Jung Bok Lee, Els Van Nieuwenhuysen, et al.. (2024). A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ENGOT-ov80 study).. Journal of Clinical Oncology. 42(16_suppl). TPS5627–TPS5627. 4 indexed citations

Bressel, Mathias, Yi-An Ko, Anne Hamilton, et al.. (2024). Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5565–5565. 1 indexed citations

Kampan, Nirmala Chandralega, Catherine Itsiopoulos, Katie L. Flanagan, et al.. (2024). Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies. Cancers. 16(24). 4187–4187. 3 indexed citations

Blanc‐Durand, Félix, Etienne Rouleau, Antoine Vasseur, et al.. (2023). PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches. A44.1–A44.

Scott, Clare L., et al.. (2023). Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Therapeutic Advances in Medical Oncology. 15. 2602380–2602380. 13 indexed citations

Blanc‐Durand, Félix, Christopher M. Kramer, Etienne Rouleau, et al.. (2023). 788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches. Annals of Oncology. 34. S529–S530.

Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200. 9 indexed citations

Xu, Zhen, Cassandra J. Vandenberg, Elizabeth Lieschke, et al.. (2021). CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors. Molecular Cancer Research. 19(8). 1350–1360. 11 indexed citations

10.

Vandenberg, Cassandra J., Gwo‐Yaw Ho, Ksenija Nesic, et al.. (2021). Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation.. Cancer Research. 81(13). 2 indexed citations

11.

Klein, Oliver, Damien Kee, Ben Markman, et al.. (2020). Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research. 26(17). 4454–4459. 116 indexed citations

12.

Bagnoli, Marina, Tingyan Shi, Charlie Gourley, et al.. (2019). Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells. 8(3). 200–200. 6 indexed citations

13.

Ho, Gwo‐Yaw, Holly E. Barker, Cassandra J. Vandenberg, et al.. (2018). SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models. European Journal of Cancer. 103. 1 indexed citations

14.

Hurley, Rachel M., Ksenija Nesic, Olga Kondrashova, et al.. (2018). Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance. 78(13). 1 indexed citations

15.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. UCL Discovery (University College London). 1 indexed citations

16.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations

17.

Wiegmans, Adrian P., Amber E. Alsop, Michael Bots, et al.. (2011). Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737. Cancer Research. 71(10). 3603–3615. 45 indexed citations

18.

Hussain, Khalid, Benjamin Challis, Nuno Rocha, et al.. (2011). An Activating Mutation of AKT2 and Human Hypoglycemia. Science. 334(6055). 474–474. 114 indexed citations

19.

Buckley, Patrick G., Uwe Menzel, Tiit Mathiesen, et al.. (2005). Comprehensive DNA Copy Number Profiling of Meningioma Using a Chromosome 1 Tiling Path Microarray Identifies Novel Candidate Tumor Suppressor Loci. Cancer Research. 65(7). 2653–2661. 38 indexed citations

20.

Burnham, Kim, Lorraine Robb, Clare L. Scott, Meredith O’Keeffe, & Ken Shortman. (2000). Effect of Granulocyte-Macrophage Colony-Stimulating Factor on the Generation of Epidermal Langerhans Cells. Journal of Interferon & Cytokine Research. 20(12). 1071–1076. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact